Viral Genetics Inc. is a biotechnology company with a focus on protein-based therapeutic and diagnostic products with applications in infectious disease, autoimmune conditions, and immunological deficiency. The company and its management team are key players in the fight against HIV/AIDS, infectious disease, and autoimmune deficiency. Viral Genetics has been working since 1995 to find a cure for HIV/AIDS and is based in Azusa, California.

VRAL develops its products based on thymus nuclear protein (TNP), a processed extract of mammalian thymus tissue. It has developed a lead product, VGV-1, which is a suspension of TNP in alum adjuvant for the treatment of HIV infection and AIDS. VGV-1 is currently in the preclinical stage of development in the United States, but outside of the USA it is in later stage development. Viral Genetics believes that VGV-1 represents a significant and unique approach to treating HIV due to the apparently novel mechanism, low toxicity